Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Non-Current Deffered Revenue: 2024

Historic Non-Current Deffered Revenue for Day One Biopharmaceuticals (DAWN) over the last 1 years, with Dec 2024 value amounting to $3.2 million.

  • Day One Biopharmaceuticals' Non-Current Deffered Revenue fell 3.53% to $3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.0 million, marking a year-over-year decrease of 3.53%. This contributed to the annual value of $3.2 million for FY2024, which is N/A change from last year.
  • As of FY2024, Day One Biopharmaceuticals' Non-Current Deffered Revenue stood at $3.2 million.
  • Over the past 5 years, Day One Biopharmaceuticals' Non-Current Deffered Revenue peaked at $3.2 million during FY2024, and registered a low of $3.2 million during FY2024.
  • Its 1-year average for Non-Current Deffered Revenue is $3.2 million, with a median of $3.2 million in 2024.